Nabi Biopharmaceuticals is a biotech company focused on developing products that encompass two main areas of treatment; nicotine addiction, and bacterial infections.

NicVAX® is Nabi’s weapon against nicotine addiction/relapse, and as its name suggests, comes in vaccination form. Nicotine is absorbed through the lungs into the blood, where it is subsequently carried to the brain; more specifically, to nicotine receptors in the brain. This results in the dispersal of natural stimulants, and produces the desirable sensation that smokers find addicting. NicVAX® stimulates the system into producing nicotine antibodies, which in turn bond with any nicotine molecules in the bloodstream, and prevents them from reaching the brain.

StaphVAX® is a vaccination developed by Nabi that produces antibodies which are critical in fighting certain bacterial infections; most commonly the infection known as S. aureus (also known as Golden Staph, the most common of the Staphylococcus infections). In laymen’s terms, chemicals found